Segui
Luca Moscetti
Luca Moscetti
Azienda Ospedaliero Universitaria Policlinico Modena
Email verificata su policlinico.mo.it
Titolo
Citata da
Citata da
Anno
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
MC Garassino, O Martelli, M Broggini, G Farina, S Veronese, E Rulli, ...
The lancet oncology 14 (10), 981-988, 2013
5792013
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N Harbeck, P Rastogi, M Martin, SM Tolaney, ZM Shao, PA Fasching, ...
Annals of Oncology 32 (12), 1571-1581, 2021
2952021
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial
C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts, V Gebbia, P Maione, ...
Journal of Clinical Oncology 30 (24), 3002-3011, 2012
2762012
Triple positive breast cancer: a distinct subtype?
P Vici, L Pizzuti, C Natoli, T Gamucci, L Di Lauro, M Barba, D Sergi, ...
Cancer treatment reviews 41 (2), 69-76, 2015
1462015
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)
F Di Costanzo, P Carlini, L Doni, B Massidda, R Mattioli, A Iop, E Barletta, ...
British journal of cancer 93 (2), 185-189, 2005
1342005
Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center
A Fabi, A Felici, G Metro, A Mirri, E Bria, S Telera, L Moscetti, M Russillo, ...
Journal of Experimental & Clinical Cancer Research 30, 1-7, 2011
1332011
Natural history of non-small-cell lung cancer with bone metastases
D Santini, S Barni, S Intagliata, A Falcone, F Ferraù, D Galetta, L Moscetti, ...
Scientific reports 5 (1), 1-9, 2015
1122015
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era
A Toss, C Isca, M Venturelli, C Nasso, G Ficarra, V Bellelli, C Armocida, ...
ESMO open 6 (2), 100055, 2021
892021
Up‐front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: Survey by Outcome Research Network for Evaluation of Treatment …
L Moscetti, F Nelli, A Felici, M Rinaldi, S De Santis, G D'Auria, G Mansueto, ...
Cancer 109 (2), 274-281, 2007
872007
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
S De Placido, C Gallo, M De Laurentiis, G Bisagni, G Arpino, MG Sarobba, ...
The Lancet Oncology 19 (4), 474-485, 2018
802018
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
C Omarini, G Guaitoli, S Pipitone, L Moscetti, L Cortesi, S Cascinu, ...
Cancer management and research, 91-103, 2018
722018
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
P Vici, L Pizzuti, A Michelotti, I Sperduti, C Natoli, L Mentuccia, L Di Lauro, ...
Oncotarget 8 (34), 56921, 2017
702017
Intra-arterial liver chemotherapy and hormone therapy in malignant insulinoma: case report and review of the literature
L Moscetti, R Saltarelli, R Giuliani, G Fornarini, M Bezzi, E Cortesi
Tumori Journal 86 (6), 475-479, 2000
682000
Current challenges in HER2-positive breast cancer
F Puglisi, C Fontanella, V Amoroso, GV Bianchi, G Bisagni, C Falci, ...
Critical Reviews in Oncology/Hematology 98, 211-221, 2016
592016
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
P Vici, L Pizzuti, C Natoli, L Moscetti, L Mentuccia, A Vaccaro, D Sergi, ...
Breast cancer research and treatment 147, 599-607, 2014
592014
Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study
T Gamucci, A Michelotti, L Pizzuti, L Mentuccia, E Landucci, I Sperduti, ...
Journal of Cancer 5 (5), 320, 2014
592014
T-DM1 and brain metastases: clinical outcome in HER2-positive metastatic breast cancer
A Fabi, D Alesini, E Valle, L Moscetti, R Caputo, M Caruso, L Carbognin, ...
The Breast 41, 137-143, 2018
562018
Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis
T Gamucci, A Vaccaro, F Ciancola, L Pizzuti, I Sperduti, L Moscetti, ...
Journal of cancer research and clinical oncology 139, 853-860, 2013
552013
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study …
J Gligorov, B Ataseven, M Verrill, M De Laurentiis, KH Jung, HA Azim, ...
European Journal of Cancer 82, 237-246, 2017
502017
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial
E Rulli, M Marabese, V Torri, G Farina, S Veronese, A Bettini, F Longo, ...
Annals of Oncology 26 (10), 2079-2084, 2015
482015
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20